Drug Companies: Procedural Focus Belies Government’s Weakness In Drug-Pricing Case
WILMINGTON, Del. — Briefing by the government on its recent drug price negotiation law focuses on procedural issues because it lacks footing for an actual argument on the merits, a drugmakers...To view the full article, register now.
Already a subscriber? Click here to view full article